BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

... Danielle Golovin, Staff Writer Elzonris (tagraxofusp-erzs, SL-401) Gamifant, emapalumab-lzsg (NI-0501) Adakveo, crizanlizumab (SEG101, selg1) Arikayce, amikacin (alis, amikacin liposome inhalation suspension, arikace, slit amikacin) Ayvakit...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership...
BioCentury | Feb 18, 2020
Finance

Canada’s Sagard gaining healthcare foothold via royalty fund

Canadian alternative asset management firm Sagard Holdings is dipping its toe into life sciences investments via a new royalty fund, which has raised $475 million in a first close. The firm isn’t disclosing the final...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

...disease therapy Arikayce amikacin (see “Insmed In-licenses DPP-1 Inhibitor from AstraZeneca” ). In September 2018, Arikayce...
BioCentury | Dec 19, 2019

Benzoxaborole-based CPSF3 inhibitor to treat infections

DISEASE CATEGORY: Infectious disease INDICATION: Cryptosporidium Inhibiting the Cryptosporidium CPSF3 homolog with AN3661 could treat infections by the parasite, which can be lethal in young children and immunocompromised individuals. Anacor Pharmaceuticals Inc., which Pfizer Inc....
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BioCentury | Oct 3, 2019
Finance

Tenaya to deploy $92M series B to develop heart disease platforms in parallel

For its $92 million series B round, Tenaya sought a syndicate willing to invest enough that the company could advance heart disease programs from multiple modalities toward the clinic simultaneously. The company's regenerative medicine and...
BioCentury | Sep 3, 2019
Financial News

Achilles adds £100M to move neoantigen T cell therapy into the clinic

Achilles added blue chip investors in its series B round to finance the progression of its neoantigen T cell therapy platform into the clinic. New investor RA Capital led the £100 million ($121.3 million) series...
Items per page:
1 - 10 of 325